NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics said today that it has licensed exclusive rights from Vancouver's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) to commercialize gene expression tests for prognosis of COPD patients who will experience frequent lung attacks.

HTG Molecular Diagnostics said it plans to use the PROOF Centre's testing technology to develop an assay on its qNPA platform, and that the Centre will help to clinically validate the test in Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.